Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH.
CHLOROMYXIN vs SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. Sequential blockade produces bactericidal effect.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
One double-strength tablet (160 mg trimethoprim/800 mg sulfamethoxazole) orally every 12 hours.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Sulfamethoxazole: 9-11 hours; trimethoprim: 8-11 hours. In severe renal impairment (CrCl <15 mL/min), half-life prolongs significantly (up to 30 hours for trimethoprim).
CHLOROMYXIN is not a recognized drug. No data available.
Both sulfamethoxazole and trimethoprim are primarily excreted via the kidneys. Sulfamethoxazole: ~30% as unchanged drug, ~50% as N4-acetyl metabolite; trimethoprim: ~80% as unchanged drug. Fecal elimination is minimal (<5%).
Category C
Category D/X
Antibiotic
Antibiotic